Green-Swan Pharmaceuticals Competitors and Similar CompaniesClear all

Green-Swan Pharmaceuticals's competitors and similar companies include Luyan Pharmaceutical, Samil Pharmaceutical, Marcan Pharmaceuticals and Dompe.

	Green-Swan Pharmaceuticals Green-Swan Pharmaceuticals is a company that manufactures and distributes drugs, medical devices, and dietary supplements.	Luyan Pharmaceutical Luyan Pharmaceutical (鲁燕药业) is a company that produces, distributes, and sells human health products.	Samil Pharmaceutical Samil Pharmaceutical (삼일제약주) is a manufacturer and supplier of medical devices and pharmaceutical products.	Marcan Pharmaceuticals Marcan Pharmaceuticals is a company that manufactures and distributes medications.	Dompe Dompe is a biopharmaceutical company engaged in research, development, and production of therapeutic solutions.
Founding Date	Founding Date 1997	Founding Date 1992	Founding Date 1947	Founding Date N/A	Founding Date 1940
Type	Type Private	Type Public	Type Public	Type Private	Type Private
Tags	Tags Healthcare distribution drug development medical devices pharma supplements	Tags Healthcare distribution drug development medical devices pharma	Tags Healthcare distribution drug development medical devices pharma supplements	Tags Healthcare distribution drug development medical devices pharma	Tags Healthcare biotech cosmetics distribution drug development medical devices pharma supplements
Locations	Locations CZ HQ	Locations Xia Men Shi, CN HQ	Locations KR HQ	Locations Ottawa, CA HQ	Locations Milano, IT HQ Tiranë, AL L'aquila, IT Napoli, IT Boston, US see more
Employees	Employees 72	Employees 5,602	Employees 586	Employees 522% increase	Employees 1,0411% increase
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) ¥20.3b (FY, 2024)	Revenue (est.) ₩219.7b (FY, 2024)	Revenue (est.) N/A	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods ¥18.9b (FY, 2024)	Cost of goods ₩138.8b (FY, 2024)	Cost of goods N/A	Cost of goods N/A
Gross profit	Gross profit N/A	Gross profit ¥1.5b (FY, 2024)	Gross profit ₩81.3b (FY, 2024)	Gross profit N/A	Gross profit N/A
Net income	Net income N/A	Net income ¥347.7m (FY, 2024)	Net income (₩5.6b) (FY, 2024)	Net income N/A	Net income N/A